Drug Profile


Alternative Names: BIIB 067; IONIS-SOD1Rx; ISIS 333611; ISIS-SOD1Rx; SODr/h333611

Latest Information Update: 27 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center for Neurologic Study; Isis Pharmaceuticals; Ludwig Institute for Cancer Research
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Amyotrophic lateral sclerosis

Most Recent Events

  • 08 Mar 2017 Biogen and Ionis Pharmaceutical initiates a phase I extension trial in Amyotrophic lateral sclerosis in USA, Canada, Belgium, Germany and United Kingdom (NCT03070119)
  • 07 Mar 2017 Biogen plans a phase I trial for Amyotrophic lateral sclerosis (NCT03070119)
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top